Renalytix shares are trading higher after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
Portfolio Pulse from Benzinga Newsdesk
Renalytix has received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test, leading to a rise in its share prices.
June 30, 2023 | 8:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Renalytix's stock price is likely to increase in the short term due to the FDA's marketing authorization for its KidneyIntelX.dkd prognostic test.
The FDA's marketing authorization for Renalytix's KidneyIntelX.dkd prognostic test is a significant positive development for the company. This approval not only validates the test's effectiveness but also opens up a new market for the company. As a result, investors are likely to react positively to this news, leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100